FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386770412> ?p ?o ?g. }

• W4386770412 abstract "Abstract Background Myocardial immunoglobulin light-chain (AL) amyloid deposits trigger heart failure, cardiomyocyte stretch and myocardial injury, leading to adverse cardiac outcomes. Positron emission tomography/computed tomography (PET/CT) with 18 F-florbetapir, a novel amyloid-targeting radiotracer, can quantify left ventricular (LV) amyloid burden, but its prognostic value is not known. Therefore, we aimed to evaluate the prognostic value of LV amyloid burden quantified by 18 F-florbetapir PET/CT and to identify mechanistic pathways mediating its association with outcomes. Methods Eighty-one participants with newly-diagnosed systemic AL amyloidosis were prospectively enrolled and underwent 18 F-florbetapir PET/CT. LV amyloid burden was quantified using 18 F-florbetapir LV percent injected dose (%ID). Mayo AL stage was determined using troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and difference between involved and uninvolved free light chain levels. Major adverse cardiac events (MACE) were defined as all-cause death, heart failure hospitalization, or cardiac transplantation within 12 months. Results Among participants (median age 61 years, 57% males), 36% experienced MACE. Incidence of MACE increased across tertiles of LV amyloid burden from 7% to 63% (p<0.001). LV amyloid burden was significantly associated with MACE in univariable analysis (hazard ratio 1.45, 95% confidence interval 1.15-1.82, p=0.002). However, this association became non-significant in multivariable analyses adjusted for Mayo AL stage. Mediation analysis showed that the association between 18 F-florbetapir LV %ID and MACE was primarily mediated by NT-proBNP (p<0.001), a marker of cardiomyocyte stretch and component of Mayo AL stage. Conclusion In this first study to link cardiac 18 F-florbetapir uptake to subsequent outcomes, LV amyloid burden estimated by LV %ID predicted MACE in AL amyloidosis. But this effect was not independent of Mayo AL stage. LV amyloid burden was associated with MACE primarily via NT-pro-BNP, a marker of cardiomyocyte stretch and component of Mayo AL stage. These findings provide novel insights into the mechanism through which myocardial AL amyloid leads to MACE. Clinical Perspective In systemic light-chain (AL) amyloidosis, cardiac involvement is the key determinant of adverse outcomes. Usually, prognosis is based on the Mayo AL stage, determined by troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and the difference between involved and uninvolved immunoglobulin free light chain levels (dFLC). Cardiac amyloid burden is not considered in this staging. In the present study, we used the amyloid-specific radiotracer 18 F-florbetapir to quantify left ventricular (LV) amyloid burden in 81 participants with newly-diagnosed AL amyloidosis and evaluated its prognostic value on major adverse outcomes (MACE: all-cause death, heart failure hospitalization, or cardiac transplantation within 12 months). We found that higher LV amyloid burden by 18 F-florbetapir positron emission tomography/computed tomography (PET/CT) was strongly associated with MACE. However, this association became non-significant after adjustment for the Mayo AL stage. Mediation analysis offered novel pathophysiological insights, implying that LV amyloid burden leads to MACE predominantly through cardiomyocyte stretch and light chain toxicity (by NT-proBNP), rather than through myocardial injury (by troponin T), also considering the severity of plasma cell dyscrasia (by dFLC). This mediation by NT-proBNP may explain why the association with outcomes was non-significant with adjustment for Mayo AL stage. Together, these results establish quantitative 18 F-florbetapir PET/CT as a valid method to predict adverse outcomes in AL amyloidosis. These results support the use of 18 F-florbetapir PET/CT to measure the effects of novel fibril-depleting therapies, in addition to plasma cell therapy, to improve outcomes in systemic AL amyloidosis." @default.
• W4386770412 created "2023-09-16" @default.
• W4386770412 creator A5000578249 @default.
• W4386770412 creator A5005111256 @default.
• W4386770412 creator A5024591457 @default.
• W4386770412 creator A5041448254 @default.
• W4386770412 creator A5044226573 @default.
• W4386770412 creator A5045641510 @default.
• W4386770412 creator A5049595422 @default.
• W4386770412 creator A5051672881 @default.
• W4386770412 creator A5052626419 @default.
• W4386770412 creator A5056428329 @default.
• W4386770412 creator A5065496916 @default.
• W4386770412 creator A5071439155 @default.
• W4386770412 creator A5080799305 @default.
• W4386770412 creator A5084430398 @default.
• W4386770412 creator A5084831561 @default.
• W4386770412 date "2023-09-15" @default.
• W4386770412 modified "2023-10-14" @default.
• W4386770412 title "Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis" @default.
• W4386770412 cites W1769623626 @default.
• W4386770412 cites W1870217140 @default.
• W4386770412 cites W1994877692 @default.
• W4386770412 cites W2084522929 @default.
• W4386770412 cites W2088110121 @default.
• W4386770412 cites W2093879134 @default.
• W4386770412 cites W2114581617 @default.
• W4386770412 cites W2171033052 @default.
• W4386770412 cites W2193561325 @default.
• W4386770412 cites W2443994174 @default.
• W4386770412 cites W2522056109 @default.
• W4386770412 cites W2599076725 @default.
• W4386770412 cites W2802991944 @default.
• W4386770412 cites W2887075678 @default.
• W4386770412 cites W2898144881 @default.
• W4386770412 cites W2928963245 @default.
• W4386770412 cites W2947988761 @default.
• W4386770412 cites W2970218258 @default.
• W4386770412 cites W2970261800 @default.
• W4386770412 cites W2979730941 @default.
• W4386770412 cites W2994164822 @default.
• W4386770412 cites W3003392328 @default.
• W4386770412 cites W3024557448 @default.
• W4386770412 cites W3025657113 @default.
• W4386770412 cites W3046992262 @default.
• W4386770412 cites W3174070807 @default.
• W4386770412 cites W3198090182 @default.
• W4386770412 cites W3200678634 @default.
• W4386770412 cites W3200948809 @default.
• W4386770412 cites W3205616210 @default.
• W4386770412 cites W3210373320 @default.
• W4386770412 cites W4200176843 @default.
• W4386770412 cites W4200296375 @default.
• W4386770412 cites W4248429808 @default.
• W4386770412 cites W4382182358 @default.
• W4386770412 doi "https://doi.org/10.1101/2023.09.13.23295520" @default.
• W4386770412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37745589" @default.
• W4386770412 hasPublicationYear "2023" @default.
• W4386770412 type Work @default.
• W4386770412 citedByCount "0" @default.
• W4386770412 crossrefType "posted-content" @default.
• W4386770412 hasAuthorship W4386770412A5000578249 @default.
• W4386770412 hasAuthorship W4386770412A5005111256 @default.
• W4386770412 hasAuthorship W4386770412A5024591457 @default.
• W4386770412 hasAuthorship W4386770412A5041448254 @default.
• W4386770412 hasAuthorship W4386770412A5044226573 @default.
• W4386770412 hasAuthorship W4386770412A5045641510 @default.
• W4386770412 hasAuthorship W4386770412A5049595422 @default.
• W4386770412 hasAuthorship W4386770412A5051672881 @default.
• W4386770412 hasAuthorship W4386770412A5052626419 @default.
• W4386770412 hasAuthorship W4386770412A5056428329 @default.
• W4386770412 hasAuthorship W4386770412A5065496916 @default.
• W4386770412 hasAuthorship W4386770412A5071439155 @default.
• W4386770412 hasAuthorship W4386770412A5080799305 @default.
• W4386770412 hasAuthorship W4386770412A5084430398 @default.
• W4386770412 hasAuthorship W4386770412A5084831561 @default.
• W4386770412 hasBestOaLocation W43867704121 @default.
• W4386770412 hasConcept C126322002 @default.
• W4386770412 hasConcept C126838900 @default.
• W4386770412 hasConcept C142724271 @default.
• W4386770412 hasConcept C159654299 @default.
• W4386770412 hasConcept C164705383 @default.
• W4386770412 hasConcept C199374082 @default.
• W4386770412 hasConcept C203014093 @default.
• W4386770412 hasConcept C207103383 @default.
• W4386770412 hasConcept C2775842073 @default.
• W4386770412 hasConcept C2775846464 @default.
• W4386770412 hasConcept C2775915353 @default.
• W4386770412 hasConcept C2777607188 @default.
• W4386770412 hasConcept C2777633098 @default.
• W4386770412 hasConcept C2778198053 @default.
• W4386770412 hasConcept C2779551797 @default.
• W4386770412 hasConcept C2779951007 @default.
• W4386770412 hasConcept C2780400711 @default.
• W4386770412 hasConcept C2780739214 @default.
• W4386770412 hasConcept C36394416 @default.
• W4386770412 hasConcept C44249647 @default.
• W4386770412 hasConcept C500558357 @default.
• W4386770412 hasConcept C50382708 @default.
• W4386770412 hasConcept C71924100 @default.

• next